The overproduction of E. coli in the gut, which causes diarrhea or intestinal inflammation, can be attributed to the availability of sialic acid, found in the proteins of the intestinal mucosa, they discovered. To use sialic acid to multiply, E. coli uses the enzyme sialidase, released by other intestinal bacteria.
From there, the researchers discovered that when people take a sialidase inhibitor, the E. coli can’t multiply excessively and therefore the disease symptoms were alleviated. Flu-fighting medications serve as sialidase inhibitors.
“Derivatives of known flu agents such as Tamiflu and Relenza could therefore also be used for inflammatory intestinal diseases, which opens up new therapeutic possibilities,” said Thierry Hennet, a professor from the University of Zurich.
More articles on infections:
Respiratory infections may spread via personal clothing, study finds
Study findings support giving flu vaccines to the elderly
Flu vaccines effective for 6 months, study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
